FDA Panel Says No to Experimental ALS Drug, NurOwn

THURSDAY, Sept. 28, 2023– An advisory panel to the U.S. Food and Drug Administration on Wednesday voted resoundingly against recommending, NurOwn, a stem cell-based experimental treatment for ALS. Although the FDA isn ' t bound by the votes of...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news